Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2860845 | 0.79 | CES1 (0.39) | ALDH1A1FFAR3TSHR | |
| SCHEMBL14370458 | 0.78 | ALDH1A1 (0.45) | TDP1ALDH1A1FFAR3HMGCRCHRM1 | |
| Hydrogen Sulfide SCHEMBL28099743 | 0.76 | ALDH1A1 (0.43) | TDP1ALDH1A1FFAR3HMGCRCHRM1 | |
| SCHEMBL2863276 | 0.75 | FAAH (0.45) | ALDH1A1 | |
| SCHEMBL16599779 | 0.75 | — | — | |
| SCHEMBL10693856 | 0.74 | TDP1 (0.42) | TDP1ALDH1A1FFAR3GAA | |
| SCHEMBL4140338 | 0.74 | TDP1 (0.42) | TDP1ALDH1A1FFAR3GAA | |
| SCHEMBL2871597 | 0.74 | FAAH (0.54) | TDP1ALDH1A1TSHR | |
| SCHEMBL8027762 | 0.73 | — | — | |
| SCHEMBL3668666 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012054527-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| CN-101115403-B | flavouring ingredient | FIRMENICH S.A. (CH) | 2011-11-30 | — | — | CN | disclosed |
| US-7794767-B2 | Flavoring ingredients | FIRMENICH SA (CH) | 2010-09-14 | — | — | US | disclosed |
| EP-1858351-B1 | FLAVORING INGREDIENTS | FIRMENICH & CIE (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1858351-A1 | FLAVORING INGREDIENTS | FIRMENICH SA (CH) | 2007-11-28 | — | — | EP | disclosed |
| US-20070259088-A1 | FLAVORING INGREDIENTS | FIRMENICH SA (CH) | 2007-11-08 | — | — | US | disclosed |
| WO-2006092749-A1 | FLAVORING INGREDIENTS | FIRMENICH SA (CH) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | TDP1 3786/4885ALDH1A1 796/4885FFAR3 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.